Janux Therapeutics (JANX) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OPKO Health (OPK) has outperformed Janux Therapeutics (JANX) over the past year, losing 9.7% versus a loss of 21.0%. Over five years, JANX leads with a -15.2% price change compared with -62.6% for OPK. Janux Therapeutics is the larger company by market cap ($1.13 billion vs $1.02 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | OPK |
|---|---|---|
| Share price | $18.50 | $1.37 |
| Market cap | $1.13B | $1.02B |
| 1-day change | +3.24% | -1.44% |
| YTD return | +29.86% | +10.32% |
| 1-year return | -21.02% | -9.74% |
| 5-year return | -15.19% | -62.63% |
| EPS (TTM) | $-1.64 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $1.75 |
| 52-week low | $12.12 | $0.98 |
| Distance from 52-week high | -47.65% | -21.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +95.89% | +219.71% |
| Average volume | 836.60K | 3.35M |
| Shares outstanding | 61.14M | 746.33M |
| Employees | 113 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OPK has outperformed JANX by 11.3 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
JANX vs OPK FAQ
Which is bigger, Janux Therapeutics or OPKO Health?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.13B compared with $1.02B for OPKO Health (OPK).
Which stock has performed better over the past year, JANX or OPK?
OPK returned -9.74% over the past 12 months, compared with -21.02% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.